Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study-Reference-Cited by-同舟云学术

Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study

Published:2020-08 Issue:8 Volume:15 Page:1317-1327
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Suzuki Yuzo^ORCID,Karayama Masato,Uto Tomohiro,Fujii Masato,Matsui Takashi,Asada Kazuhiro,Kusagaya Hideki,Kato Masato,Matsuda Hiroyuki,Matsuura Shun,Toyoshima Mikio,Mori Kazutaka,Ito Yasuhiro,Koyauchi Takafumi,Yasui Hideki,Hozumi Hironao,Furuhashi Kazuki,Enomoto Noriyuki,Fujisawa Tomoyuki,Nakamura Yutaro,Inui Naoki,Suda Takafumi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities;Cancer Immunology, Immunotherapy;2024-09-05

2. The impact of chronic obstructive pulmonary disease on the risk of immune-related pneumonitis in lung cancer patients undergoing immunotherapy: a systematic review and meta-analysis;BMC Pulmonary Medicine;2024-08-14

3. Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors;PLOS ONE;2024-07-16

4. Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy;Anticancer Research;2024-06-26

5. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis;The Oncologist;2024-06-17